Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. North America Pharmaceutical CRO Market, 2019-2030, $ bn 19
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CRO Market 25
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical CRO Market 30
Figure 9. Investment Opportunity Analysis 34
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical CRO Market 37
Figure 11. Breakdown of North America Pharmaceutical CRO Market by Service, 2019-2030, % of Sales Revenue 42
Figure 12. North America Addressable Market Cap in 2020-2030 by Service, Value ($ bn) and Share (%) 42
Figure 13. North America Pharmaceutical CRO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 43
Figure 14. North America Pharmaceutical CRO Market: CRO for Phase I Trials, 2019-2030, $ bn 44
Figure 15. North America Pharmaceutical CRO Market: CRO for Phase II Trials, 2019-2030, $ bn 45
Figure 16. North America Pharmaceutical CRO Market: CRO for Phase III Trials, 2019-2030, $ bn 46
Figure 17. North America Pharmaceutical CRO Market: CRO for Phase IV Trials, 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical CRO Market: Laboratory Services, 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical CRO Market: Consulting Services, 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical CRO Market: Data Management Services, 2019-2030, $ bn 50
Figure 21. Breakdown of North America Pharmaceutical CRO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 52
Figure 22. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 52
Figure 23. North America Pharmaceutical CRO Market: Infectious Diseases, 2019-2030, $ bn 53
Figure 24. North America Pharmaceutical CRO Market: Oncology, 2019-2030, $ bn 54
Figure 25. North America Pharmaceutical CRO Market: Metabolic Disorders, 2019-2030, $ bn 55
Figure 26. North America Pharmaceutical CRO Market: Cardiovascular Disorders, 2019-2030, $ bn 56
Figure 27. North America Pharmaceutical CRO Market: Central Nervous System, 2019-2030, $ bn 57
Figure 28. North America Pharmaceutical CRO Market: Respiratory Disorders, 2019-2030, $ bn 58
Figure 29. North America Pharmaceutical CRO Market: Gastrointestinal Disorders, 2019-2030, $ bn 59
Figure 30. North America Pharmaceutical CRO Market: Other Therapeutic Applications, 2019-2030, $ bn 60
Figure 31. Breakdown of North America Pharmaceutical CRO Market by End User, 2019-2030, % of Revenue 62
Figure 32. North America Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%) 62
Figure 33. North America Pharmaceutical CRO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 63
Figure 34. North America Pharmaceutical CRO Market: Medical Device Companies, 2019-2030, $ bn 64
Figure 35. North America Pharmaceutical CRO Market: Academic Institutes, 2019-2030, $ bn 65
Figure 36. Breakdown of North America Pharmaceutical CRO Market by Country, 2019 and 2030, % of Revenue 68
Figure 37. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 69
Figure 38. U.S. Pharmaceutical CRO Market, 2019-2030, $ bn 71
Figure 39. Canada Pharmaceutical CRO Market, 2019-2030, $ bn 74
Figure 40. Pharmaceutical CRO Market in Mexico, 2015-2030, $ bn 76
Figure 41. Growth Stage of North America Pharmaceutical CRO Industry over the Forecast Period 78
North America pharmaceutical CRO market is expected to grow by 7.3% annually in the forecast period and reach $37.61 billion by 2030 driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity. Highlighted with 26 tables and 41 figures, this 106-page report “North America Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country. Based on Service, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmaceutical CRO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK North America Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More